Synthekine nabs megaround in bid to edge out Merck, Sanofi in IL-2 sprint

Nine months after launching out of Stanford with $82 million and a portfolio of engineered cytokines, Synthekine has landed a $107.5 million Series B from Deerfield Management and others to push their two lead cancer programs into the clinic.